Asian Currencies Trade Mixed as Yen Hovers Near 40-Year Low, Dollar Holds Firm on Fed Outlook 
Oil Prices Rebound as Strait of Hormuz Tensions Return After Ship Attack Near Oman 
Wall Street Ends Lower as AI Stocks Drag Markets, Fed Rate Outlook Shifts 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
BOJ Hawk Signals Faster Interest Rate Hikes Amid Inflation Risks 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
South Korea’s KOSPI Jumps Over 5% as Samsung, SK Hynix Rally on Micron Earnings Boost 
S&P Affirms Brazil’s BB Credit Rating with Stable Outlook Amid Fiscal Challenges 
US Dollar Slips After PCE Inflation Data Eases Fed Rate Hike Expectations 
Asian Stocks Sink as Apple Price Hikes Spark AI Valuation Fears, South Korea and Japan Lead Selloff 
Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
Australia Jobs Growth Strengthens Rate Hike Outlook 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Johnson & Johnson is joining the other major pharmaceutical company in challenging President Biden's administration’s Inflation Reduction Act which gives Medicare more powers to trim down prices of medicines.
This week, Johnson & Johnson sued the government to fight the Medicare drug price negotiation. According to CNBC, the lawsuit was filed at a New Jersey federal district court, and the company stated the Medicare negotiations are a violation of the First and Fifth Amendments of the U.S. Constitution.
Prior to Johnson & Johnson’s lawsuit filing, Merck and Bristol Myers Squibb have also brought their respective complaint to the court for the same case. It was reported that the U.S. Chamber of Commerce and PhRMA have also made similar disputes against the controversial IRA provision.
In its complaint, the New Jersey-headquartered pharmaceutical company asked the court to stop the U.S. Health and Human Services Department from forcing them to be involved in the program.
“Today, we filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services to challenge the innovation-damaging drug pricing provisions of the Inflation Reduction Act (IRA),” Johnson & Johnson said in a statement. “The IRA breaks the agreement at the heart of the patent and regulatory laws: when companies invest and succeed at developing innovative new treatments, they are awarded time-limited and constitutionally protected rights in their innovation.”
It added, “With the implementation of the IRA, the government is forcing Janssen to provide its innovative, patented medicines on pricing terms that by law must be significantly below market prices. We have a responsibility to challenge the current version of the law to protect our ability to continue developing transformative medicines for patients now and in the future.”
Photo by: Johnson & Johnson Media Center
